Close

Vaccitech plc (VACC) Reports FY22, Issues Update on Corporate Developments

Go back to Vaccitech plc (VACC) Reports FY22, Issues Update on Corporate Developments

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

March 24, 2023 8:07 AM EDT

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Companys progress.

2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment... More